Amphastar Pharmaceuticals (AMPH) Long-Term Debt Repayments (2013 - 2026)

Amphastar Pharmaceuticals' Long-Term Debt Repayments history runs 14 years deep, the most recent figure standing at $29000.0 for Q1 2026.

• In Q1 2026, Long-Term Debt Repayments fell 23.68% year-over-year to $29000.0; the TTM figure through Mar 2026 stood at $214000.0 (down 97.39% YoY), while the FY2025 annual figure was $223000.0, down 97.3% from the prior year.
• Long-Term Debt Repayments was $29000.0 for Q1 2026 at Amphastar Pharmaceuticals, down from $104000.0 in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $200.1 million in Q3 2023 to a low of $29000.0 in Q1 2026.
• Historically, Long-Term Debt Repayments has averaged $19.4 million across 5 years, with a median of $128000.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Long-Term Debt Repayments jumped 39081.25% in 2023, then slumped 99.98% in 2024.
• A 5-year view of Long-Term Debt Repayments shows it stood at $128000.0 in 2022, then surged by 39081.25% to $50.2 million in 2023, then slumped by 99.77% to $115000.0 in 2024, then decreased by 9.57% to $104000.0 in 2025, then sank by 72.12% to $29000.0 in 2026.
• The last three Long-Term Debt Repayments figures came in at $29000.0 (Q1 2026), $104000.0 (Q4 2025), and $44000.0 (Q3 2025), per Business Quant data.